Related Experiment Videos
Protein-protein interactions in human disease.
Daniel P Ryan1, Jacqueline M Matthews
1School of Molecular and Microbial Biosciences, University of Sydney, Sydney, New South Wales 2006, Australia.
Current Opinion in Structural Biology
|July 5, 2005
Summary
Abnormal protein-protein interactions drive many diseases. Developing targeted therapeutics requires detailed molecular understanding to inhibit these disease-causing interactions effectively.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Many human diseases stem from aberrant protein-protein interactions (PPIs).
- These interactions can involve endogenous proteins, pathogen proteins, or both.
- Inhibiting these abnormal associations holds significant clinical potential.
Purpose of the Study:
- To highlight the clinical significance of targeting PPIs in disease.
- To underscore the necessity of detailed molecular insights for therapeutic design.
- To review recent advancements in identifying and characterizing disease-related PPIs.
Main Methods:
- Identification and characterization of specific PPIs in various disease contexts.
- Exploration of diverse approaches for generating PPI inhibitors.
- Focus on molecular and atomic-level understanding of interaction systems.
Main Results:
- Specific disease-associated PPIs have been identified in systems like cervical cancer, bacterial infections, leukemia, and neurodegenerative diseases.
- Various strategies are emerging for the development of PPI inhibitors.
- Detailed molecular knowledge is crucial for designing effective therapeutics.
Conclusions:
- Targeting PPIs is a promising therapeutic strategy for numerous human diseases.
- Continued research into the molecular mechanisms of PPIs is essential for drug development.
- Developing inhibitors of abnormal PPIs offers a pathway to novel treatments.